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Alveolar macrophageMavrilimumab (CAM-3001) is an investigational human IgG4monoclonal antibody (MAb) targeting GM-CSF re-
ceptor alphawhich is currently being developed for the treatment of RA. GM-CSF plays a central role in the path-
ogenesis of rheumatoid arthritis (RA) through the activation, differentiation, and survival of macrophages and
neutrophils. To support clinical development, the nonclinical safety of mavrilimumab was evaluated in several
studies with cynomolgus monkeys as the pharmacologically relevant species. Comprehensive toxicity parame-
ters were assessed in each study, and treatment duration ranged from 4 to 26 weeks. Mavrilimumab has an ac-
ceptable safety proﬁle inmonkeys with no changes in any parameters other thanmicroscopic ﬁndings in lung. In
several studies, minimal accumulation of foamy alveolar macrophages was observed. This ﬁnding was only seen
in studies of at least 11 weeks duration, was reversible following a dose-free recovery period andwas considered
non-adverse. At higher dose levels (≥30 mg/kg/week), in a 26-week repeat-IV dose study, the presence of lung
foreignmaterial, cholesterol clefts, and granulomatous inﬂammationwas also observed in a few animals andwas
considered adverse. The dose- and time-related accumulation of foamymacrophages in lung following exposure
to mavrilimumab observed in several NHP studies was expected based upon the known role of GM-CSFRα sig-
naling in the function of alveolar macrophages. Overall, a clean no-observed-adverse-effect-level (NOAEL) with-
out any effects in lung was established and provided adequate clinical safety margins. In clinical studies in RA
patients, mavrilimumab has demonstrated good clinical activity with adequate safety to support further clinical
development. A Phase 2b study of mavrilimumab in subjects with RA is in progress.
© 2014MedImmune, LLC. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Mavrilimumab is a human IgG4 Mab which binds GM-CSFRα to
neutralize GM-CSF activity. A recently completed Ph2a randomized,
double-blind, placebo-controlled study showedmavrilimumab induced
rapid clinically signiﬁcant responses in RA subjects suggesting that sup-
pressing neutrophil and macrophage activity by targeting the GMCSF
receptor may provide an effective and novel therapeutic approach for
RA (Burmester et al., 2013; EARTH NCT00771420).
Given the central role of GM-CSF signaling in alveolar macrophages
for the regulation of pulmonary surfactant homeostasis, lung toxicitySafety Assessment,MedImmune,
301 398 9387.
ier Inc. This is an open access article uis a potential concern for agents such as mavrilimumab which target
the GM-CSF pathway (Trapnell and Whitsett, 2002). The role of GM-
CSF in the regulation of lung surfactant homeostasis and alveolarmacro-
phage innate immune function in the lung is based in part on evidence
from mice in which GM-CSF signaling is ablated (Dranoff et al., 1994;
Stanley et al., 1994). In these GMCSF knockout (GM KO) mice, accumu-
lation of phospholipids and proteins in lung is seen resulting from an in-
hibition of surfactant catabolism and reduced clearance by alveolar
macrophages. In humans, pulmonary alveolar proteinosis (PAP) is a
heterogeneous group of rare restrictive lung disorders characterized
by the accumulation of surfactant lipids and proteins in pulmonary alve-
olar macrophages resulting in respiratory insufﬁciency, and in severe
cases, respiratory failure. Some forms of hereditary PAP are associated
with mutations in the genes encoding the GM-CSF receptor while
autoimmunePAP is characterized byhigh levels of anti-GM-CSF autoan-
tibodies (Carey and Trapnell, 2010). Because GM-CSF plays a role in thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
231P.C. Ryan et al. / Toxicology and Applied Pharmacology 279 (2014) 230–239regulation of pulmonary surfactant homeostasis, lung toxicity is a
potential concern for biologics such as mavrilimumab which inhibit
GM-CSF receptor signaling. As a result, additional attention was given
to the potential impact of lung toxicity during the development of
mavrilimumab.
Materials and methods
Test and control article. Mavrilimumab is a fully human IgG4 mono-
clonal antibody targeting the GMCSF receptor alpha. It is expressed in
CHO cells, puriﬁed by chromatography and formulated in 50 mM
sodium acetate/acetic acid, 100mMsodium chloride, 0.02% polysorbate
80, pH 5.5 allowing a ﬁnal concentration of product of 100 mg/mL. Con-
trol article was formulation buffer, 50 mM sodium acetate/acetic acid,
100 mM sodium chloride, 0.02% polysorbate 80, pH 5.5.
Nonhuman primate studies. Nonhumanprimate (NHP) toxicity studies
were performed in male and female cynomolgus monkeys at AAALAC-
accredited laboratories. All study protocols were approved by testing fa-
cility Institutional Animal Care and Use Committee. Two non-GLP and
ﬁve GLP-compliant toxicity studies were performed ranging in treatment
duration from 4 to 26 weeks using once weekly intravenous (IV) or sub-
cutaneous (SC) injection of mavrilimumab or vehicle control. In some
studies, a separate cohort of animals was necropsied after a dose-free re-
covery period ranging in duration from 4 to 17 weeks. Study designs,
dose levels and numbers of animals per group for each study are summa-
rized in Table 1.
Comprehensive toxicology parameters were assessed in each study
including physical examinations, body weights, food consumption, be-
havior, ophthalmology, ECGs, clinical chemistry, urinalysis, hematology,
organweights, macroscopic andmicroscopic pathological observations.
In some studies, bronchoalveolar lavage (BAL) samples were collected
and evaluated microscopically to enumerate cell types present in BAL.
Blood samples were collected at various timepoints and analyzed for
determination of serum concentrations of mavrilimumab and the pres-
ence of anti-drug antibodies (ADA).
Bioanalysis. Concentrations ofmavrilimumab in cynomolgusmonkey
serumwere determined using a validated ELISA on a Gyrolab immuno-
assay platform (Quotient Bioresearch, Cambridge, England). Each of 112
microstructures on a Gyrolab Bioaffy CD contained a column prepacked
with streptavidin-coated beads which were functionalized with a bio-
tinylated human GM-CSFR-Fc fusion protein as the capture reagent.
Upon mavrilimumab binding a ﬂuorophor labeled detection reagent
(sheep anti-human IgG4) was then added and ﬂorescence signals
were determined. The lower limit of quantitation (LLOQ) of the validat-
ed assay was 50 ng/mL. For the 26 week SC study (Study 7 in Table 1),
the method for the quantitation of mavrilimumab in cynomolgus mon-
key serum was developed and validated at ALTA Analytical Laboratory
(San Diego, CA). This method utilized an electrochemiluminescent
(ECL) assay format to measure the concentration of mavrilimumab in
cynomolgus monkey serum. An MSD Streptavidin Coated Standard
MA2400 96-Well Plate was ﬁrst incubated with CAM-3020 Biotin
(anti-mavrilimumab monoclonal antibody). After incubation, Standards/
QCs and samples were added to the plate. Unbound material was then
washed away and Sheep anti-Human IgG4 SulfoTAG was added to the
plate. After incubation,mavrilimumabwas detectedwithMSDRead Buff-
er T (1×) and read on the Meso Scale Discovery (MSD) SectorTM Imager
2400. The assay lower limit of quantiﬁcation (LLOQ) was 0.375 ng/mL.
The presence of ADA in monkey serum was detected using an
electrochemiluminescent immunoassay. Biotinylated mavrilimumab
and ruthenylated mavrilimumab were allowed to form a complex with
the ADA and these ADA-bridged complexes were subsequently captured
by the streptavidin-coated MSD plate containing embedded carbon elec-
trodes. Upon electrical excitation the ECL signals were detected by the
MSD Sector™ Imager. Pooled normal monkey serum was used as thenegative control and a monoclonal antibody against mavrilimumab
served as the positive control. The assay cut point factor was 2.02, and
the assay sensitivity was estimated to be approximately 800 ng/mL.
Pharmacokinetic data analysis. Noncompartmental toxicokinetic data
analysis was performed using WinNonlin Professional (version 5.2,
Pharsight Corp., San Louis, MO). The area under serum concentration–
time curves (AUC) were estimated by the linear/log trapezoidal rule.
After SC administration of mavrilimumab the maximum concentration
(Cmax) was recorded as observed. Nominal collection times were used
for the TK data analyses.
The steady-state PK exposure in adult subjects with rheumatoid ar-
thritis was projected using a mechanistic model previously developed
to describe the disposition ofmavrilimumab, GM-CSFRα binding, recep-
tor internalization and subsequent intra-cellular degradation (Minter et
al., 2012; Wang et al., 2012). Based on the simulated PK proﬁles, the
projected steady-state Cmax and AUC were calculated and compared
with those observed in cynomolgus monkeys at NOAEL dose level. In
toxicology studies cynomolgus monkeys received weekly mavrilimumab
administrations. In human subjectswith RA,mavrilimumabwas adminis-
tered once every other week. To account for the difference in dosing fre-
quency, the observed steady-state weekly AUC in cynomolgus monkeys
was doubled prior to the comparison (Table 6).
Results
The nonclinical safety of mavrilimumab was evaluated in several
repeat-IV and SC dose toxicology studies in cynomolgus monkeys. Cy-
nomolgus monkeys were selected as the pharmacologically relevant
species based on the similar binding afﬁnity of mavrilimumab to cyno-
molgus monkey GM CSFRα compared to the human receptor and the
lack of binding to rodent GM CSFRα (Minter et al., 2012). The activity
of mavrilimumab was further tested in a functional assay against cells
expressing cynomolgus monkey GM CSFRα by pA2 analysis using a
granulocyte shape-change assay and shown to be active and equally po-
tent on monkey cells compared to human cells (Minter et al., 2012).
Seven independent repeat-dose toxicity studies were performed in
cynomolgus monkeys. The dosing phase of the studies ranged from 4
to 26 weeks duration and utilized once weekly IV or SC injections of
mavrilimumab. Five of the studies were performed in compliance with
Good Laboratory Practices (GLP). In some studies, a negative control
group was administered formulation buffer. In some studies, a dose-
free recovery phasewas included in the study design to examine revers-
ibility of effects. In each of these studies, there were no treatment-
related changes in clinical observations, body weights, clinical pathology
parameters, urinalysis, immunophenotyping, organ weights, and macro-
scopic or microscopic pathologic ﬁndings in any tissues other than lung.
All IV studies utilized mg/kg dosing and all SC studies utilized ﬁxed
dosing without correcting for body weight. The rationale for this was
to be consistent with the human clinical program which initially used
mg/kg IV dosing for the ﬁrst-time-in-human study and then switched
to SC ﬁxed mg dosing for Phase 2. Compared with weight-based dosing
(mg/kg), ﬁxed dosing (mg) is more convenient for SC dose administra-
tion and is associated with a lower risk of dosing error. Furthermore,
ﬁxed dosing can lead to reduced variability for some monoclonal anti-
bodies and is recommended for adult human clinical trials of monoclo-
nal antibodies (Wang et al., 2009). For the sake of making comparisons
between nonclinical studies that used mg/kg IV doses and mg ﬁxed SC
doses, the typical body weight per animal of 2.5 kg is used as a denom-
inator for each ﬁxed SC dose. This “correction factor” is not the actual
mean body weight for each study but merely a rough approximation.
Since themajority of PK variability is unexplainable by bodyweight, uti-
lizing the typical instead of individually observed body weight as the
“correction factor” is not expected to have any major impact on cross-
study comparisons.
Table 1
Summary overview of repeat-dose toxicology studies of mavrilimumab in cynomolgus monkeys.
Study no./type Objective Study design and dose levels Results
1: Non-GLP 11-week IV study. To explore potential lung toxicity following
repeat-IV dosing up to 11 weeks.
Doses 0, 10, 30 and 100 mg/kg/week;
N = 3 females/group; 4 females in
100 mg/kg group
Foamy macrophages in lung at high doses only;
NOAEL 100 mg/kg/week
2: GLP 4-week IV study with
4-week recovery.
To support ﬁrst-in-human single ascending
dose IV dose study of mavrilimumab in RA
subjects.
Doses 0, 10, 30 and 100 mg/kg/week;
N = 5/sex/group; 3/sex/group for 10 mg
No lung ﬁndings; NOAEL 100 mg/kg/week
3: Non-GLP 26-week IV study. To explore potential lung toxicity following
repeat-IV dosing in a chronic setting up to
26 weeks.
Doses 35 and 100 mg/kg/week (no control);
N = 4 females/group
Foamy macrophages in lung at both doses; NOAEL
100 mg/kg/week
4: GLP SC Bridging 4-week study
with 6-week recovery
To supportmultiple ascending dose SC study
in RA subjects.
Doses 50, 100, 200 mg/week (no control);
N = 4 males/group
No lung ﬁndings; NOAEL 200 mg/week
5: GLP 26-week IV study with
17-week recovery
To support chronic administration in RA
subjects with high margins of safety.
Doses 0, 15, 30, 100 mg/kg/week;
N = 8/sex/group
Foamy macrophages in lung all dose levels;
Adverse ﬁndings in lung at 30 and 100 mg/kg/week;
NOAEL 15 mg/kg/week
6: GLP 13 week SC study with
17-wk recovery
To characterize toxicity of SC administration
in well-controlled GLP-compliant study in
both sexes.
Doses 0, 50, 150, 400 mg/week;
N = 6/sex/group
Foamy macrophages at all doses; Reduced incidence
at end of recovery; NOAEL = 400 mg/week
7: GLP SC low dose 26-week
study with 9-week recovery
To establish a no-effect-level dose for lung
effects in a chronic study.
Doses 0, 3, 10 mg/week;N = 10/sex/group;
6/sex in control
No lung ﬁndings; NOEL = 10 mg/week
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order in Table 1 to reﬂect how the nonclinical program progressed to
support clinical development of mavrilimumab. The ﬁrst study (Study
1) was an exploratory study to examine the potential lung effects of
mavrilimumab given the available literature on the role of the target
pathway in maintaining lung homeostasis in knockout mice (Robb
et al., 1995; Stanley et al., 1994). The second study (Study 2) was a
GLP-compliant 4 week repeat-IV dose study designed to support the
ﬁrst-in-human study of mavrilimumab, a single ascending IV dose
study in RA subjects (Burmester et al., 2011). Males and females and a
vehicle control group were included in this pivotal NHP study to satisfy
regulatory requirements. The third study (Study 3) was a further explor-
atory study to examine the potential for lung toxicity following a 26-week
dosing phase given the intended chronic use ofmavrilimumab in the clin-
ical setting. The rationale for including only females in the two early ex-
ploratory non-GLP studies was to simplify the study design, to reduce
the total number of animals and because sex differences in the toxicity
proﬁle were not anticipated. The fourth study (Study 4) was a GLP-
compliant study in males to support the transition from IV to SC dosing
in the clinical program. The reason this study included only males and
no vehicle control group is because this study was designed as a stream-
lined bridging study to focus on local effects following SC administration.
In parallel to this SC bridging study, the ﬁfth study (Study 5), a 26-week
GLP repeat-IV dose study in males and females, was performed. This
study was intended to be the pivotal study to fully characterize systemic
toxicity and to support chronic dosing in the clinic. Later in development,
because of the minimal design of the 4 week SC bridging study in males,
and because the clinical program transitioned exclusively to SC dosing,
the sixth study (Study 6) was conducted to satisfy regulatory require-
ments with a more robust design, including males and females, three
dose levels and a vehicle control group. Finally, the seventh study
(Study 7) was conducted using very low SC doses to satisfy a regulatory
requirement to establish a no-effect-level dose for lung toxicity.
It is important to explain the impact of ADAs on the interpretation of
toxicity ﬁndings for mavrilimumab. Mavrilimumab is a human IgG that
cross-reacts with cynomolgus GM-CSFRα. The immunogenicity assay to
measure ADAsutilizedmavrilimumab as both the capture and detection
reagent (double-sandwich assay), and theoretically detected the pres-
ence of both binding- and neutralizing ADAs. The TK assay utilized a
fusion protein hGM-CSFR-Fc as the capture reagent and sheep anti-
human IgG as the detection reagent. As such, the TK assay measured
the unbound, biologically active mavrilimumab molecule. The reduced
TKexposure observed in the presence of ADA suggests that themajority,
if not all, of these detected ADAs were neutralizing antibodies, blocking
the interaction of mavrilimumab with the target antigen receptor. Assuch the TK exposure–response relationship in nonhuman primates
and the safety margin assessments were based on the measured un-
bound (free), biologically active mavrilimumab. All ADA positive ani-
mals are excluded from determination of mean TK parameters.
Overall, lung was identiﬁed as the target organ of toxicity following
chronic dosing with mavrilimumab. An increase in foamymacrophages
in lung tissues was observed in studies of longer duration (i.e., all stud-
ies of 11 weeks or longer) but not in two independent studies of only
4 weeks duration. Where this ﬁnding occurred in the absence of any
changes in lung structure or function, or any other changes in toxicology
parameters, a NOAELwas identiﬁed. In a single study, at higher IV doses
after 26 weeks of chronic dosing, adverse ﬁndings in lung were observed
in some animals in addition to the accumulation of foamy macrophages
(Study 5). These adverse changes included the presence of lung foreign
material, cholesterol clefts, and granulomatous inﬂammation.
In both a GLP 4-week repeat-IV dose study (Study 2) and a GLP
4-week repeat-SC dose bridging study (Study 4), no ﬁndings were ob-
served in the lungs up to the highest dose tested (100 mg/kg/week IV
or 200 mg/week SC; corresponding to body weight scaled dose level of
approximately 80 mg/kg) providing evidence that treatment-related
changes in lung requires dosing longer than 4 weeks. In studies of longer
duration, the incidence and severity of the ﬁndings in lungwere demon-
strated to bemavrilimumabdose-related. In a non-GLP 11-week IV study
in female cynomolgus monkeys (Study 1), dose-related increased num-
bers of foamymacrophageswas seenmicroscopically in 1 of 3 animals at
30 mg/kg/week and in 4 of 4 animals at 100 mg/kg/week. This ﬁnding
was only seen following microscopic examination of hematoxylin and
eosin (H&E) sections of lung tissue and was given a severity grade of
very slight to slight. Foamy macrophage changes were not observed fol-
lowingmicroscopic examination of BAL samples from this study suggest-
ing analysis of BAL is a less sensitive measure for this ﬁnding compared
to H&E. In a longer study (a non-GLP 26-week IV study in female cyno-
molgus monkeys; Study 3), this dose-related ﬁnding of increased lung
foamy macrophages was evident in both lung H&E sections and in BAL
samples. In this study, histopathological ﬁndings showed the accumula-
tion of foamy macrophages was slight to minimal in 4 of 4 animals at
35 mg/kg/week and in 4 of 4 animals at 100 mg/kg/week. Evaluation
of BAL samples after 26 weeks of treatment in ADA-negative animals
showed that the percent of foamy macrophages was higher at the
100 mg/kg/week dose compared to 35 mg/kg/week (Table 2).
In a 26-week GLP repeat-IV dose study (Study 5), the severity of the
ﬁnding of increased foamy macrophages was likewise dose-related. In
this study, the ﬁnding was minimal to moderate in severity in animals
dosed at 15 and 30 mg/kg/week and slight to marked in severity at
100 mg/kg/week. Adverse ﬁndings in lung were observed in some
Table 2
Percent foamy macrophages in BAL in ADA-negative animals of non-GLP 26 week repeat
IV dose study (Study 3).
Dose (mg/kg/week) Pre-dose baseline Post-dose week 26
35 (N = 4) 1.4 12
100 (N = 3) 2.6 31.1
233P.C. Ryan et al. / Toxicology and Applied Pharmacology 279 (2014) 230–239animals in this study and included the presence of foreign material or
endogenous cell debris (crystalline, needle shaped) in the lung of one
30 mg/kg/week male (13755), one 100 mg/kg/week male (14071),
and one 100 mg/kg/week female (14081) at the end of the dosing
phase (terminal necropsy) and in one 30 mg/kg/week male (14053)
at the end of the recovery period (recovery necropsy). Bronchioalveolar
hyperplasia was also observed in some of these animals: in one
100 mg/kg/week male (14071) at the terminal necropsy and in one
30 mg/kg/week (14053) and one 100 mg/kg/week male (14059) at
the recovery necropsy. Of these animals, the 30 mg/kg/week male in
the recovery group had the most affected lung, with moderate foamy
macrophages, severe ﬁbrosis, marked areaswith needle shaped crystal-
line deposits consistent with cholesterol crystals/clefts in the lung with
associated granulomatous inﬂammation, marked bronchioalveolar hy-
perplasia, and slight inﬂammation of the bronchioles (Fig. 1C). The
lung lesion in this animal was considered to be severe granulomatous
inﬂammation associated with lipoproteinic material (potentially cho-
lesterol) fromdegradation of lung surfactant. The presence of thismate-
rial combined with the exaggerated granulomatous inﬂammatory lung
lesions at higher doses (30 and 100 mg/kg/week) was considered ad-
verse, and may reﬂect the impaired ability of alveolar macrophages to
clear inhaled foreign material or endogenous cell debris. In this study,
the no-observed-adverse-effect-level (NOAEL) was considered the
low dose, 15 mg/kg/week.Fig. 1. Representative photomicrographs of histologic ﬁndings in lungs of cynomolgus monkey
cation from a terminally euthanized high dose animal 14081 (100 mg/kg/week) depicts multif
nally euthanized high dose animal 14071 (100 mg/kg/week) showsmarked accumulation of fo
magniﬁcation of most highly effected animal 14053 from recovery necropsy mid-dose (30 mg
cholesterol clefts (H&E 20×).Representative photomicrographs of lungs from mavrilimumab-
treated animals are shown in Figs. 1 and 2. In the 26 week GLP
repeat-IV dose study (Study 5), dose-related accumulation of
foamy macrophages in lung tissue sections observed in a high dose
(100 mg/kg/week) female (Fig. 1A) and male (Fig. 1B) at the end of
the treatment phase is shown. In the same study, adverse ﬁndings
were observed in lungs in some animals at higher doses (30 and
100 mg/kg/week). The lung pathology observed in one 30 mg/kg/week
male (Fig. 1C) was considered to be severe granulomatous inﬂammation
associated with lipoproteinic material (cholesterol) from degradation of
lung surfactant. Theseﬁndings represent an exaggerated pharmacological
effect arising from prolonged mavrilimumab blockade of GM-CSF signal-
ing and inhibitory effects on lung macrophage function. The lung lesions
observed in these NHP studies are consistent with lung lesions observed








Milder effects were seen in the 13-week repeat-SC dose study
(Study 6) and included only minimal accumulation of foamy macro-
phages at the terminal necropsy in some animals at all dose levels
without evidence of granulomatous inﬂammation, cholesterol clefts or
any other adverse changes. Foamy macrophages are a common back-
ground ﬁnding in cynomolgus monkeys (Drevon-Gaillot et al., 2006)
and at the lowest dose in this study (50 mg/week or approximately
20 mg/kg/week), foamy macrophages were only marginally increased
compared to the background incidence seen in control animals. At the
highest dose (400 mg/week or approximately 160 mg/kg/week),s from a 26-week GLP repeat-IV dose study of mavrilimumab (Study 5). A) Lowmagniﬁ-
ocal accumulation of foamy macrophages (H&E 4×). B) High magniﬁcation from a termi-
amymacrophages, foreignmaterial and granulomatous inﬂammation (H&E 40×). C) High
/kg/week) shows foamy macrophages, severe ﬁbrosis, granulomatous inﬂammation and
Fig. 2. Representative photomicrographs of histologic ﬁndings in lungs of cynomolgusmonkeys from 13-week GLP repeat-SC dose study (Study 6) at terminal necropsy showingminimal
accumulation of foamymacrophages. A) Low dose animal (50 mg/week; approximately 20 mg/kg/week). B) High dose animal (400 mg/week; approximate 160 mg/kg/week). Black ar-
rows indicate single foamy macrophages. Blue arrows indicate clusters of foamy macrophages.
Table 3
Incidence of foamymacrophages in the lung inADA-positive and ADA-negative animals of
GLP 13 week repeat sc dose study (Study 6).




234 P.C. Ryan et al. / Toxicology and Applied Pharmacology 279 (2014) 230–239while the severity of the ﬁnding was still graded “minimal,” there ap-
peared to be more clusters of foamy macrophages at the highest dose
compared with only occasional individual foamy cells the lowest
dose. Representative photomicrographs of lungs from a low dose
(50 mg/week) and a high dose (400 mg/week) animal at the terminal
necropsy are shown in Fig. 2A and B and illustrates the increased num-
bers of these cells at the higher dose compared to the lower dose. These
results conﬁrm the dose-dependency of this effect.
Partial reversibility of the ﬁnding of lung foamy macrophages was
demonstrated in several studies. In the 26 week GLP repeat-IV dose
study (Study 5), reduced frequency of foamymacrophages was observed
at the end of a 17-week dose-free period compared to end-of dosing al-
though foamy macrophages were still present. At recovery, the foamy
macrophages tended to be found clustered in hilar and subpleural loca-
tions, rather than diffuse throughout the lung. The distribution of these
cells in the periarteriolar and peribronchiolar locations at recovery is
viewed as evidence of a recovery process, as this is the location where al-
veolar macrophages enter lymphatics and exit the lung (Courtice, 1963).
Partial reversibility of foamy macrophages was also observed in a 13
week repeat-SC dose study (Study 6) following weekly SC injections of
0, 50, 150 or 400 mg/week (approximately 0, 20, 60 and 160 mg/kg/
week). In this study, minimal accumulation of foamy macrophages was
seen at all dose levels at the end of the dosing phase. At the end of recov-
ery, this minimal ﬁndingwas primarily observed in the periarteriolar and
peribronchiolar regions of the lung (lung hilus) suggesting that these cells
were being cleared from the lung. Further evidence of the reversibility of
foamymacrophageswas the reduced number of animalswith thisﬁnding
at the end of the recovery period. Overall,minimal accumulation of foamy
alveolar macrophages was observed in 13 of 18 mavrilimumab-treated
animals at the end of the dosing period, while this ﬁnding was observed
in only 9 of 18 animals at the end of a 17 week dose-free recovery
phase (Table 3). In this study, the presence of ADA did not impact the
lung ﬁndings and all animals were similarly exposed to active drug as
measured in the TK assay. For that reason, both ADApositive andnegative
animals are included in Table 3. Notably, at the lowest dose, the fewestrecovery animals were affected, suggesting that reversibility of this ﬁnd-
ing may take longer at higher doses.
Toxicokinetics
The TK properties of mavrilimumab in cynomolgus monkeys indicate
a potential antigen sink effect related to GM-CSFRα-mediated clearance
of mavrilimumab at low serum concentration levels. At higher serum
concentrations, the PK of mavrilimumab was apparently linear with
dose. No gender difference in PK was observed. The elimination t1/2 of
mavrilimumab was 1–2 weeks, typical for a human IgG in cynomolgus
monkeys. The absorption of SC administered mavrilimumab from the
dosing site was slow, the peak serum concentration was observed
2–4 days postdose (Tmax). A summary of mean noncompartmental TK
parameters in ADA-negative animals from a GLP 26 week repeat-IV
dose study (Study 5) is shown in Table 4 and that in ADA-negative an-
imals from a GLP 13 week repeat-SC dose study (Study 6) is shown in
Table 5. The absolute SC bioavailability ofmavrilimumab in cynomolgus
monkeys was not formally determined in toxicology studies. However,
by comparing the TK exposure across different IV and SC toxicology
studies, the SCbioavailability ofmavrilimumab in cynomolgusmonkeys
was predicted to be in the range of 50% to 100%.
Mean time versus concentration proﬁles for the GLP13week repeat-
SC dose study (Study 6) for ADA-negative animals are shown in Fig. 2. At
these dose levels, dose proportional PK was observed with no evidence
of receptor mediated clearance. Notably, given the long elimination
Table 4
Noncompartmental TK parameters in ADA negative cynomolgus monkeys in 26 week GLP repeat IV dose study (Study 5).
TK parametersa Dose (mg/kg once per week)
15 30 100
Week 1 Week 26 Week 1 Week 26 Week 1 Week 26
AUCτ (μg · d/mL) 1110 (269) 6450 (1020) 1850 (410) 10,600 (2843) 6420 (936) 31,200 (7870)
Cmax (μg/mL) 357 (96.6) 1260 (436) 540 (111) 2420 (656) 2150 (539) 7150 (2050)
t1/2 (d) 6.27 (0.938) 8.68 (3.57) 8.26 (2.27) 9.24 (4.70) 6.38 (1.34) 10.9 (4.67)
a Parameters are rounded to 3 signiﬁcant ﬁgures, and shown as mean (standard deviation). AUCτ = area under the concentration–time curve at steady-state in the 7-day dosing in-
terval; Cmax = maximal observed concentration; SC = subcutaneous; TK = toxicokinetics.
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stantial exposure to mavrilimumab persisted throughout the recovery
phase (Fig. 3).
Immunogenicity and establishment of no observed effect level
Mavrilimumab is immunogenic in cynomolgus monkeys, and the
immunogenicity response upon repeated dosing had a profound impact
on clearance of mavrilimumab in repeat-dose studies. Thus, immunoge-
nicity severely confounded the ability to investigate the effects of low re-
peated doses of mavrilimumab to establish a no observed effect level
(NOEL). Nevertheless, a low repeat-SC dose study (Study 7) was con-
ducted to formally identify a dose level that did not lead to accumulation
of foamy macrophages in lung following chronic dosing. To account for
the predicted high rate of ADA at these low doses, large numbers of an-
imals per groupwere used (N= 10/sex/group). Animals got onceweek-
ly SC injections at 3 or 10 mg/week (corresponding to body weight
scaled dose levels of approximately 1.2 and 4 mg/kg/week, respectively)
for 26 weeks. As predicted, the majority of animals developed ADA
which led to rapid clearance. TK exposure was maintained in 4 ADA-
negative animals at 10 mg/week and in 1 ADA-negative animal at
3 mg/week. No ﬁndings were observed in any animals in this study and
the NOEL is considered 10 mg/week (approximately 4 mg/kg/week).
Impact of ADA on clearance is illustrated in the time–concentration
proﬁles for individual animals in this 26-week low repeat-SC dose
study (Study 7) in which the majority of animals developed anti-drug
antibodies (Figs. 4 and 5). These TK proﬁles demonstrate that serum
concentrations of mavrilimumab decreased rapidly to below the lower
limit of quantitation in all ADA-positive animals while animals that
were ADA negative maintained exposure to mavrilimumab throughout
the dosing phase. Prevalence of ADAs across all studies as a function of
IV or SC mavrilimumab dose is depicted in Fig. 6. There is a clear trend
for increasing ADA prevalence with decreasing mavrilimumab dose.
As a consequence, maintaining exposure at low dose levels is hindered
by the interfering ADA response which confounds the ability to fully
characterize the toxicity effects of low mavrilimumab dose levels.
Exposure response relationship and safety margins
The incidence of the ﬁnding of accumulation of foamymacrophages
as a function of mavrilimumab exposure (AUC) in ADA-negativeTable 5
Noncompartmental TK parameters in ADA negative cynomolgus monkeys in 13 week GLP rep
TK parametersa Dose (mg once per week; ﬁxed dose)
50 150
Week 1 Week 13 Week 1
AUCτ (μg · d/mL) 1000 (243) 3920 (1140) 3130 (64
Cmax (μg/mL) 175 (50.8) 691 (238) 560 (130
t1/2 (d) ND 9.64 (3.77) ND
a Parameters are rounded to 3 signiﬁcant ﬁgures, and shown as mean (standard deviation).
terval; Cmax = maximal observed concentration; SC = subcutaneous; TK = toxicokinetics; Nanimals in three GLP studies (26 week repeat-IV dose, 13 week
repeat-SC dose and 26 week repeat-low SC dose; Studies 5, 6, and 7)
was analyzed in order to characterize the exposure–response relation-
ship. By comparing the incidence of foamy macrophages versus AUC
(0 − t) in ADA-negative animals across multiple NHP studies, it is
clear that the probability of observing foamy macrophages in lung in-
creases with dose (Fig. 7). There is a biphasic relationship between the
probability of observing this ﬁnding as a function of log10AUC suggest-
ing that exposure to mavrilimumab must be above a critical threshold
level before pharmacologically-mediated lung ﬁndings are observed.
The safety margin for the accumulation of foamy macrophages was
calculatedby comparingpredictedhumanexposures andobservedTKex-
posure in the lowSC repeat-dose study in cynomolgusmonkeys (Study 7)
at the NOEL of 10 mg/week mavrilimumab (Table 6). Because minimal
accumulation of foamy macrophages in lung could be considered an un-
acceptable toxicity by certain health authorities, this was intended to be
the deﬁnitive study to establish the mavrilimumab exposure safety mar-
gin. Human exposure to mavrilimumab was modeled based on available
data from the completed EARTH study (Burmester et al., 2013) to predict
the human exposures at the dose levels of 30, 100, and 150 mg
mavrilimumabSC every otherweek (Q2W)under evaluation in the ongo-
ing Phase 2b clinical study (EARTH Explorer 1; NCT01706926). At the
NOEL of 10 mg/week, the mean values of Cmax and AUCτ at steady-state
were 83.3 μg/mL and 338 μg · d/mL, respectively. By comparing human
and cynomolgus monkey exposures, the calculated safety margins for
the ongoing Ph2b study are 38.6, 5.54, and 3.69, respectively (Table 6).
In order to graphically depict the therapeutic window or safety mar-
gin, the incidence of foamy macrophages (percent of animals with the
ﬁnding) versus exposure (AUC0–7d) across all completed chronic GLP tox-
icology studies in ADA-negative monkeys is shown in Fig. 8. The three
vertical colored lines represent the predicted correspondent human
AUCτ at each humandose level (30, 100, 150mgQ2W). The human expo-
sures are at least 10-fold below the monkey exposure levels associated
with the ﬁnding of foamymacrophages in lung demonstrating an accept-
able safety margin for continued mavrilimumab clinical development.Discussion
Mavrilimumab demonstrated an acceptable safety proﬁle in several
repeat-IV and SC dose studies in cynomolgusmonkeys with no changes
in any of the evaluated parameters and no microscopic ﬁndings in anyeat SC dose study (Study 6).
400
Week 13 Week 1 Week 13
4) 13,300 (2340) 11,800 (2620) 44,300 (8830)
) 2150 (397) 2220 (676) 7590 (1410)
11.6 (2.37) ND 14.0 (2.23)
AUCτ = area under the concentration–time curve at steady-state in the 7-day dosing in-
D = not determined.
Fig. 3.MeanTKproﬁles inGLP13week repeat-SCdose study (Study6).Meanmavrilimumab
serumconcentrations in μg/mLversus time are shown forADA-negative animals in eachdose
group.
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phages in lung tissues was observed in several studies following long-
term dosing (at least 11 weeks) and is predictable based on the pharma-
cology of inhibiting normal GM-CSF function (Trapnell and Whitsett,
2002; Uchida et al., 2009; Yoshida et al., 2001).
Catabolism of surfactant by alveolar macrophages requires GM-CSF
signaling (Reed and Whitsett, 1998; Reed et al., 2000; Yoshida et al.,
2001). The foamy appearance of alveolar macrophages, therefore, re-
ﬂects the intracellular accumulation of neutral lipids within these cells
resulting from target-mediated functional inhibition as opposed to an
inﬂammatory response consisting ofmixed cellular inﬁltration, or an in-
crease in total macrophages in the lung. Where this occurred in the ab-
sence of any other changes in the pulmonary anatomic pathology or
any other toxicology parameters, a NOAEL was identiﬁed. In a GLP
26-week repeat-IV dose study (Study 5), the presence of lung foreign
material, cholesterol clefts, and granulomatous inﬂammation was ob-
served in some animals at higher doses and was considered adverse.Fig. 4. Individual TK proﬁles in GLP 26 week repeat-SC dose study at 3 mg per week (Study 7).
with once weekly doses of 3 mg mavrilimumab. At week 5 and later, ADA-positive animals haThis exaggerated response to lung foreign material and cholesterol
clefts is consistent with mavrilimumab inhibitory effects on lung mac-
rophage function.
Signiﬁcant work has been done to characterize alveolar macrophage
responses to inhaled small molecule therapeutics and these effects can
pose regulatory challenges for development of inhaled medicines
(Forbes et al., 2014; Lewis et al., 2014). The mavrilimumab effects in
nonhuman primates described here can be compared and contrasted
with the effects described for inhaled small molecules. While there is
similarity in the phenotype of many of the ﬁndings, there are consider-
able differences in the underlying biology leading to these lung effects
for inhaled small molecules compared to a systemically administered
GM-CSF inhibitor such that designation of a “class effect” is not straight-
forward. In many cases, poorly soluble inhaled small molecules can
induce macrophage responses such as the accumulation of foamy mac-
rophages. These lesionsmay ormay not be associatedwith neutrophilic
inﬂammation (Lewis et al., 2014). The challenge to inhaled small mole-
cule development has been distinguishing non-adverse phagocytic
adaptive responses from adverse responses (Forbes et al., 2014).
While these ﬁndings may be caused by deposition of particulates, they
may also be modulated by the pharmacological action of these agents.
In the case of mavrilimumab, which is a parenterally administered
large molecule (i.e. not directly instilled into the lung), the best inter-
pretation of the observed lung ﬁndings is that blockade of GM-CSFRα
signaling in alveolar macrophages inhibits their ability to catabolize
the lipoproteineic material that comprises surfactant. The alveolarmac-
rophage response in inhaled small molecule drug development has
been described as a common but a poorly understood phenomenon
that requires development of optimized models and batteries of tests
to better characterize the alveolar macrophage response (Forbes et al.,
2014). As a result, the signiﬁcance of the accumulation of foamymacro-
phages differs. That is, for small molecules deposited directly into the
lung, the ﬁnding largely reﬂects impaired clearance of particulate mat-
ter, while for mavrilimumab it reﬂects blockade of a critical cytokine
receptor signaling pathway. Despite these differences, we share the
opinion of the authors in Lewis et al. that foamymacrophage accumula-
tion without associated inﬂammatory changes should be considered a
non-adverse effect. Furthermore, the wealth of scientiﬁc evidence
available in the literature supports the pharmacological basis for theMavrilimumab serum concentrations in μg/mL versus time for individual animals treated
d serum levels below lower limit of quantitation (LLOQ).
Fig. 5. Individual TK proﬁles in GLP 26week repeat-SC dose study at 10mg per week (Study 7). Mavrilimumab serum concentrations in μg/mL versus time for individual animals treated
with once weekly doses of 10 mg mavrilimumab. At week 5 and later, ADA-positive animals had serum levels below lower limit of quantitation (LLOQ).
237P.C. Ryan et al. / Toxicology and Applied Pharmacology 279 (2014) 230–239mavrilimumab induced lung effectswhile for the broad range of inhaled
small molecule drugs, improved understanding of alveolar macrophage
biology is important to advancing the development of drugs that cause
these effects.
Mavrilimumab is immunogenic in cynomolgus monkeys, and the de-
velopment of ADA is associated with substantially reduced exposures. As
ADA greatly facilitates the systemic clearance of mavrilimumab, at lower
dose levels the potentially high prevalence of ADA in cynomolgus mon-
keys predictably would preclude the ability to achieve and maintain
meaningful TK exposure in these animals. Nevertheless, to formally
demonstrate the NOEL dose of mavrilimumab in a chronic setting, a low
SC 26-week repeat-dose study was performed in cynomolgus monkeys
(Study 7). In this study, animals got once weekly SC injections at 3
or 10 mg for 26 weeks. TK exposure was maintained in 5 ADA-
negative animals. No mavrilimumab-related effects were observedFig. 6. Prevalence of anti-drug antibodies inmavrilimumab nonhuman primate studies. The frac
group) for three mavrilimumab repeat-IV dose (Studies 2, 3 and 5) and three repeat-SC dose s
doses were converted to mg/kg dose assuming a typical animal body weight of 2.5 kg).in the lung or any other parameter assessed and the NOEL was deter-
mined to be 10 mg/week. As predicted, the majority of animals de-
veloped ADA, which led to rapid clearance of mavrilimumab.
Homeostasis of surfactant is critical for lung function and is main-
tained by the balanced production and clearance of surfactant by cells
in the lung. The ability of pulmonary alveolar macrophages to clear sur-
factant lipids and proteins from the lung surface is regulated by GM-CSF
via the transcription factor PU.1 (Trapnell andWhitsett, 2002). Blockade
of GM-CSF signalingwould therefore be expected to lead to inhibition of
alveolar macrophage function. The critical role of GM-CSF in surfac-
tant homeostasis was identiﬁed in GM-CSF−/− and in GM-Rβ chain-
deﬁcient CSF2RB−/− mice (Dranoff et al., 1994; Robb et al., 1995;
Stanley et al., 1994). In these mice, impaired clearance of surfactant by
alveolar macrophages causes surfactant accumulation and a lung phe-
notype identical to PAP in humans.tion of ADA positive animals (number of ADA+ animals/total number of animals per dose
tudies (Studies 4, 6 and 7) versus the administered dose. (Doses administered as ﬁxed SC
Fig. 7. Probability of foamy macrophages. Estimated probability of observing foamy mac-
rophages in ADA-negative animals in three GLP repeat-dose studies (Studies 5, 6 and 7) as
an increasing function of AUCτ. The dashed lines represent 95% conﬁdence limits of the es-
timated probability.
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very slowly. Broadly, PAP can be classiﬁed in 3 forms: (1) primary or id-
iopathic (autoimmune), which is the most common clinical form and
strongly associated with high levels of autoantibodies against GM-CSF;
(2) hereditary PAP which occurs in patients with defects in genes
encoding GM-CSF receptor (CSF2RA or CSF2RB) and (3) secondary,
which can be due to lung infections, hematologic malignancies and in-
halation of mineral dusts such as silica, titanium oxide, aluminium,
and insecticides. Clinically, PAP is characterized by dyspnea when
there is a substantial accumulation of surfactant proteins in alveolar
spaces (Carey and Trapnell, 2010).
Thus, PAP is a theoretical risk factor associated with GM-CSF inhibi-
tion. Although high levels of circulating autoantibodies to GM-CSF are
associated with PAP, data has shown that these GM-CSF autoantibodies
can likewise be detected in healthy individuals, albeit at much reduced
concentrations (Uchida et al., 2009). On average, PAP patients were
found to have 59.8 μg/mL serumGM-CSF autoantibody levels compared
to mean levels of 1.04 μg/mL in healthy controls (Uchida et al., 2009).
The authors propose that there is a critical threshold level of autoanti-
bodies, between about 10.4 and 19 μg/mL, above which development
of PAP is more likely (Carey and Trapnell, 2010; Uchida et al., 2009).
This “critical threshold” concept is consistentwithmavrilimumab toxic-
ity ﬁndings observed in NHP which identiﬁed an exposure level of
mavrilimumab in serum which was not associated with development
of foamymacrophages in lung (i.e. NOEL). The pulmonary alveolarmac-
rophage response observed in cynomolgus monkeys following treat-
ment with mavrilimumab was a pharmacologically-mediated ﬁnding
with a biphasic dose response (Fig. 7). Taken all together, this evidence
suggests there is a therapeutic window for the clinical use of antibody
therapies to the GM-CSF pathway in inﬂammatory diseases like RA.Table 6
Human Safety Margins for Accumulation of Lung Foamy Macrophages.
Observed human exposure (Q2W) Obser
10 m
30 mg 100 mg 150 mg a
AUCτ (μg · d/mL) 17.5 122 183 AUCτ
Cmax (μg/mL) 2.16 11.1 16.7 Cmax (
AUCτ = area under the concentration–time curve at steady-state in the 14-day dosing interv
Phase 2b; SC = subcutaneous; TK = toxicokinetics
a The safety margin is estimated based on projected 150 mg Q2W human exposure assumin
b Steady-state AUC in a 2-week interval.In the recently completed Ph2a clinical study EARTH (Burmester et al.,
2013)mavrilimumab (10, 30, 50 or 100mgQ2W) or placebowas admin-
istered SC to subjects with moderate/severe RA (DAS28 N 3.2) on stable
methotrexate for 12 weeks followed by a 12week drug free followuppe-
riod. Intensive respiratorymonitoring including chest X-rays, forced expi-
ratory volume (FEV1), forced vital capacity (FVC), diffusing capacity of the
lung for carbonmonoxide (DLCO) and dyspnea scores were incorporated
into the study objectives. In addition, serum biomarkers of lung damage,
surfactant protein D (SP-D) and Krebs von den Lungen-6 (KL-6) were
measured using commercially available immunoassays.
The biomarker SP-D is amember of the collagenous subfamily of gly-
coproteins and calcium-dependent lectins. In the lungs, SP-D partici-
pates in the innate response to inhaled microorganisms and organic
antigens. Studies have shown that expression of SP-D may be related
to a number of human diseases, including cystic ﬁbrosis (Olesen et al.,
2010), asthma (Atochina-Vasserman et al., 2011), acute interstitial
pneumonias (Kucejko et al., 2009), acute lung injury (ALI) and acute
respiratory distress syndrome (ARDS) (Ware et al., 2010), and PAP
(Sakagami et al., 2010).
The biomarker KL-6 is amember of the collagenous subfamily of gly-
coproteins secreted by type II pneumocytes and has emerged as a po-
tential surrogate biomarker of alveolitis (Hant et al., 2009). Studies
have shown that expression of KL-6 may be directly related to alveolar
damage and inﬂammation caused by lung disease, including cystic ﬁ-
brosis (Ohshimo et al., 2009), asthma (Imai et al., 2002), ARDS (Kondo
et al., 2011), and PAP (Carey and Trapnell, 2010). For this reason, SP-D
and KL-6 were evaluated across the treatment (Day 85) and safety
follow-up phase of the EARTH study (Day 169) to investigate a potential
effect of treatment with mavrilimumab on these parameters and cor-
roborate the clinical ﬁndings.
In EARTH, mavrilimumab demonstrated good clinical activity with
no clinically signiﬁcant or persistent changes in the lung function tests
performed. Likewise, the serum biomarkers of lung damage, SP-D and
KL-6, showed no clinically signiﬁcant changes following mavrilimumab
treatment. A phase 2b study in RA patients to assess safety and efﬁcacy
of mavrilimumab administered SC at 30, 100 or 150 mg Q2W over a
24 week treatment period is in progress (EARTH Explorer 1). In this
study, further pulmonary monitoring to assess potential impact on
lung safety will be evaluated.Conclusions
The dose- and time-related accumulation of foamy macrophages in
lung following exposure to mavrilimumab was observed in several
NHP studies and was expected based upon the known role of GM-
CSFRα signaling in the function of alveolar macrophages (Trapnell and
Whitsett, 2002; Uchida et al., 2009; Yoshida et al., 2001). After a dose-
free recovery period, therewas evidence of reversibility for the accumu-
lation of foamy macrophages although full recovery was not achieved.
The foamy appearance of alveolarmacrophages reﬂects the intracellular
accumulation of neutral lipids. Adverse chronic changes observed in
lung of some animals exposed to high doses of mavrilimumab wereved TK exposure at
g/week SC (Study 7)
Safety margin for proposed P2b study
30 mg 100 mg 150 mg a
(μg · d/mL) 676b 38.6 5.54 3.69
μg/mL) 83.3 38.6 7.5 4.99
al; Cmax = maximal observed concentration; NOEL = no-observed-effect level; P2b = -
g linear pharmacokinetics upon saturation of the GM-CSF receptor sink.
Fig. 8. Incidence of foamy macrophages. Percent of ADA-negative animals with positive
ﬁnding of foamymacrophages in threeGLP repeat-dose studies (Studies 5, 6 and7) is plot-
ted versus steady state AUCτ. The three vertical colored lines represent the predicted cor-
respondent human AUCτ at each human dose level (30, 100, 150 mg Q2W).
239P.C. Ryan et al. / Toxicology and Applied Pharmacology 279 (2014) 230–239characterized as an inﬂammatory reaction (granulomatous) to foreign
material and may reﬂect impaired ability of macrophages to clear for-
eign material or endogenous cell debris. Despite these ﬁndings, there
were high clinical exposure safety margins compared to the doses that
caused these adverse changes in lung. To formally identify a dose that
did not cause accumulation of foamy macrophages in lung, a low-dose
SC study was performed (Study 7). As expected, immunogenicity of
mavrilimumab led to a high rate of ADA with insufﬁcient toxicokinetic
exposures in a majority of animals. Nevertheless, exposure was main-
tained in 4 animals at 10 mg/week (approximately 4 mg/kg/week)
which represented the NOEL. The human exposures planned in Ph2b
are below the exposure levels expected to induce foamy macrophages
in lung and so are anticipated to conﬁrm the adequacy of the safetymar-
gin (3.7-fold AUC-based and 5-fold Cmax-based) to support the contin-
ued clinical development of mavrilimumab.
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